Roche Holding AG (0QOK.IL)
| Previous close | 218.55 |
| Open | 221.90 |
| Bid | 215.30 x N/A |
| Ask | 226.30 x N/A |
| Day's range | 217.90 - 221.90 |
| 52-week range | 216.50 - 298.40 |
| Volume | |
| Avg. volume | 946,793 |
| Market cap | 187.364B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 16.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.50 (3.99%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su
- Globe Newswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
- Business Wire
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi
